Search | Clinical Trials Finder

Conditions: Lung Cancer, Pulmonary Complications
Interventions: educational intervention, supervised exercise program; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 60
States / cities: Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more

Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions: Metformin, Placebo Comparator; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-Small Cell Lung Cancer
Interventions: oxaliplatin, gemcitabine, bevacizumab; Drug
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions: PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 17
States / cities: Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: BMS-986012, Carboplatin, Etoposide, Nivolumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Birmingham, Alabama • Hackensack, New Jersey • Durham, North Carolina + 4 more

Conditions: Lung Cancer
Interventions: carboplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: NSCLC, Non Small Cell Lung Cancer
Interventions: TUB-040; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • East Brunswick, New Jersey

Conditions: Non-small Cell Lung Cancer
Interventions: BIND-014; Drug
Lead sponsor: BIND Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 10
States / cities: Goodyear, Arizona • Los Angeles, California • Fort Meyers, Florida + 7 more

Conditions: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Interventions: Sotorasib, Ladarixin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Garden City, New York • Mineola, New York • New Hyde Park, New York + 1 more

Conditions: Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
Interventions: ADV/HSV-tk, Valacyclovir, SBRT, Pembrolizumab; Biological · Drug · Radiation
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumor
Interventions: DB-1310, Trastuzumab, Osimertinib, capecitabine; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: bortezomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Malignant Solid Tumour, Renal Cell Carcinoma, Non Small Cell Lung Carcinoma
Interventions: Sorafenib, Vorinostat; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Non-small Cell Lung Cancer
Interventions: Erlotinib, Hydroxychloroquine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 4
States / cities: Stanford, California • New Haven, Connecticut • Baltimore, Maryland + 1 more

Conditions: Lung Cancer
Interventions: Pemetrexed, Gemcitabine, Bevacizumab, Carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 70 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 18
States / cities: Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 14 more

Conditions: Lung Cancer, Non Small Cell Lung Cancer
Interventions: apricoxib, Placebo, Docetaxel or Pemetrexed; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 12
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 8 more

Conditions: Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer
Interventions: Durvalumab, Paclitaxel, Carboplatin, Radiation, Surgical Resection; Device · Drug · Radiation + 1 more
Lead sponsor: Greg Durm, MD; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • New York, New York + 1 more

Conditions: Lung Cancer (Non-Small Cell), Self-management Behavior, Physical Activity, Stress, Quality of Life, Resistance Training
Interventions: Breathe Easier+; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Brain Metastases, Adult, Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Interventions: Active Surveillance; Radiation
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Interventions: Divarasib, Sotorasib, Adagrasib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more

Conditions: Lung Cancer
Interventions: radiation therapy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 224
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 175 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Peripherally located lung tumor, Centrally located lung tumor; Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Histiocytosis, Hairy Cell Leukemia
Interventions: PLX8394; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington

Conditions: Non-Small Cell Lung Cancer, Carcinoma
Interventions: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T; Biological
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 14
States / cities: Duarte, California • Palo Alto, California • Miami, Florida + 11 more

Search by objective public record fields.

S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer

Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer

PF-07104091 as a Single Agent and in Combination Therapy

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer

Ladarixin With Sotorasib in Advanced NSCLC

SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Evaluating the Feasibility and Preliminary Effects of BE+

Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC